COMP <GO>
AMRX vs ALKS // EV/EBITDA & P/E VALUATION
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Alkermes plc (NASDAQ) • 15-METRIC TALLY: AMRX 5
— ALKS 8
▲ EV/EBITDA & P/E VALUATION LEADER: AMRX
LAST: $20.44 (-4.97%) • MKT CAP: $7.12B
valuation
21.4x
LAST: $44.89 (-0.99%) • MKT CAP: $7.53B
valuation
25.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. ALKS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | ALKS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 86.70% | -49.80 | ALKS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 14.00% | +0.10 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.4x | 25.1x | -3.70 | AMRX | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 6.31% | -2.68 | ALKS | /fcf-yield <GO> |
| Operating Margin | 13.10% | 17.20% | -4.10 | ALKS | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 16.40% | -14.00 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | -5.20% | +13.20 | AMRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 8.03 | -4.20 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 57.3 | -6.20 | ALKS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.05 | +0.03 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 29.3x | +66.70 | ALKS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.12B | $7.53B | -$411.7M | ALKS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | ALKS REV | AMRX GROSS % | ALKS GROSS % | AMRX FCF | ALKS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $1.48B | 36.9% | 86.7% | $269.9M | $480.3M |
| FY 2024 | $2.79B | $1.56B | 36.5% | 84.2% | $243.2M | $405.6M |
| FY 2023 | $2.39B | $1.66B | — | — | $237.9M | $326.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
ALKS // BETA 1.05